title: Role of somatostatin analogue-based therapy in unresponsive malignant thymomas.
abstract: Thymomas are rare neoplasms that are usually associated with parathymic syndromes, pure red cell aplasia, myasthenia gravis, hypogammaglobulinaemia and other mainly immunological disorders. Therefore, the management of thymoma patients is often complex and presents many diagnostic and therapeutic issues. Controversies concerning the definition of the histological subtypes and the role played by thymoma-associated syndromes are of primary importance in determining the oncological approach. Although low-stage thymomas have a high percentage of recovery, thymomas which are locally advanced, metastatic or previously treated with standard therapeutic options have no well-defined and effective treatment approaches. The data previously described by us on somatostatin receptor scintigraphy showing high uptake of indium-labelled octreotide by thymic masses and the successful treatment of a patient with thymoma and pure red cell aplasia with octreotide and prednisone has provided us the rationale for using such treatment in patients with advanced thymoma.
authors.affiliation: Department of Molecular and Clinical Oncology and Endocrinology, University Federico II, Naples, Italy. angelomartign@hotmail.com
authors.forename: G
authors.initials: G
authors.lastname: Palmieri
authors.forename: S
authors.initials: S
authors.lastname: Lastoria
authors.forename: L
authors.initials: L
authors.lastname: Montella
authors.forename: A
authors.initials: A
authors.lastname: Martignetti
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
authors.forename: M
authors.initials: M
authors.lastname: Salvatore
authors.forename: A R
authors.initials: AR
authors.lastname: Bianco
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015282:Octreotide / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013945:Thymoma / Q000175:diagnosis / Q000188:drug therapy*; D013953:Thymus Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide; D011241:Prednisone